Brokerages Set ICON Public Limited (NASDAQ:ICLR) PT at $292.45

Shares of ICON Public Limited (NASDAQ:ICLR) have received a consensus recommendation of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $290.20.

ICLR has been the topic of several research analyst reports. Redburn Atlantic assumed coverage on ICON Public in a research report on Monday, October 14th. They set a “neutral” rating and a $311.00 target price on the stock. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Barclays reduced their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Evercore ISI dropped their price objective on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Finally, TD Cowen reduced their target price on ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research note on Friday, October 25th.

Hedge Funds Weigh In On ICON Public

Large investors have recently modified their holdings of the business. Ashton Thomas Private Wealth LLC bought a new position in ICON Public in the 2nd quarter worth approximately $54,000. ORG Partners LLC purchased a new stake in ICON Public during the 2nd quarter worth about $59,000. EverSource Wealth Advisors LLC boosted its stake in ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock worth $129,000 after purchasing an additional 111 shares during the period. Whittier Trust Co. of Nevada Inc. grew its holdings in ICON Public by 119.6% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 415 shares of the medical research company’s stock valued at $130,000 after buying an additional 226 shares in the last quarter. Finally, First Horizon Advisors Inc. increased its position in shares of ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock valued at $172,000 after buying an additional 151 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

Shares of ICLR opened at $208.15 on Friday. The business has a 50-day moving average of $233.99 and a 200-day moving average of $286.74. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. The company has a market capitalization of $17.17 billion, a price-to-earnings ratio of 23.21, a price-to-earnings-growth ratio of 1.57 and a beta of 1.21. ICON Public has a 1 year low of $183.38 and a 1 year high of $347.72.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The firm had revenue of $2.03 billion during the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.10 EPS. As a group, equities research analysts anticipate that ICON Public will post 13.42 earnings per share for the current year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.